Status:
COMPLETED
Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105
Lead Sponsor:
University of Nebraska
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
19+ years
Brief Summary
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help...
Detailed Description
OBJECTIVES: * To learn the effects of selected agents (tamoxifen and aromatase inhibitors) on the profile of estrogen metabolites, glutathione conjugates, and depurinating DNA adducts in urine from w...
Eligibility Criteria
Inclusion
- Newly diagnosed ductal carcinoma in situ or invasive breast cancer
- Urine biospecimens available from participation in protocol UNMC-08105 (IRB#311-06), the Breast Cancer Collaborative Registry (BCCR), which included treatment with tamoxifen or an aromatase inhibitor
- o Urine specimens were collected at baseline, 6 months, and then annually
- Estrogen receptor or progesterone receptor positive
- ECOG performance status 0-2
Exclusion
- Not pregnant or nursing
- No concurrent use of estrogen(s)
Key Trial Info
Start Date :
February 2 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 25 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00959244
Start Date
February 2 2009
End Date
September 25 2009
Last Update
September 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eppley Cancer Center, University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-6805